PUBLISHED WORK- Barbara Arzymanow
Published work by Barbara Arzymanow is listed below under three headings: Political, Investment Advisory and Academic Research Published in Medical Journals.
Barbara Arzymanow
Political

Publication

Nature of Publication

Date  /Reference

How can A&E units improve their performance?

Click here

Guest blog written by Barbara for 2020health think tank.

January 2015

Hospital inspections: lessons to be learnt

Click here

 

Guest blog written by Barbara for 2020health think tank.

December 2014

Threats to Mankind from Drug Resistant Bacteria and Viruses

Click here

Guest blog written by Barbara for 2020health think tank.

August 2014

Are pharmaceutical mega-mergers in the public interest?

Click here

Guest blog written by Barbara for 2020health think tank.

May 2014

Medical advisory body “NICE” should not spend too much time valuing drugs.

Click      here

Guest blog written by Barbara for 2020health think tank.

April 2014

Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.

Click here

Guest blog written by Barbara for 2020health think tank.

December 2013

Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease.

Click        here

Guest blog written by Barbara for 2020health think tank.

October 2013

Pharmaceutical Industry- Innovation is the only way forward.

Click       here

Guest blog written by Barbara for 2020health think tank.

August 2013

Value-based pricing: the wrong medicine for the nation?

Click her.

Report from 2020health think tank with Barbara as main author.

May 2013

Waiting for Decisions on UK Pharmaceutical Pricing

Click here

Guest blog written by Barbara for 2020health think tank.

April 2013

Response to Department of Health Consultation on NHS Constitution

Click here

Submission to Department of Health in response to consultation document.

January 2013

Prevention is better than cure.

 

Click here .

Guest blog written by Barbara for 2020health think tank.

January 2013

Health and Social Care Act 2012:Response to Attacks on the Act

Click here

Article published on this website.

November 2012

The NHS Constitution- the turning point?

Click here

Guest blog written by Barbara for 2020health think tank.

November 2012

Think carefully about value-based drug pricing in the UK and let common sense prevail.

Click here

Guest blog written by Barbara for 2020health think tank.

September 2012

Do private patients in the UK help or harm the NHS?

 

Click here

Guest blog written by Barbara for 2020health think tank.

September 2012

The Pharmaceutical Industry – Friend or Foe?

Click here

Guest blog written by Barbara for 2020health think tank.

July 2012

Response to HM Treasury Consultation              on an 'above the line' credit for Research and Development (R&D)              

Click here

Submission to HM Treasury in response to consultation document.

June 2012

Management Priorities in the NHS under the Health and Social Care Act

Click here

Guest blog written by Barbara for 2020health think tank.

June 2012

A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.

Click here

Guest blog written by Barbara for 2020health think tank.

May 2012

The NHS needs outstanding management as well as a legal framework, for example, to unlock the potential of the property portfolio.

Click       here

Guest blog written by Barbara for 2020health think tank.

April 2012

Pharmaceutical R & D – the value of radical innovation versus incremental progress.

Click here

Guest blog written by Barbara for 2020health think tank.

March 2012

The Health and Social Care Bill: Final Stages in Parliament.

 

Click        here

Guest blog written by Barbara for 2020health think tank.

February 2012

Misleading, Biased Reporting on the Health and Social Care Bill in the Media.

Click here

Guest blog written by Barbara for 2020health think tank.

January 2012

Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011.

Click here

Guest blog written by Barbara for 2020health think tank. 

December 2011 

Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.

Click here

Guest blog written by Barbara for 2020health think tank. 

November 2011 

The highest standards of medical care urgently require doctors to remain up to date through Continuing Professional Development.

Click here

Guest blog written by Barbara for 2020health think tank.

October 2011  

What should we expect from medical and pharmaceutical R&D in the future?

Click here

Guest blog written by Barbara for 2020health think tank.

September 2011

The Patent Box.

Click here

Submission to HM Treasury in response to Further Consultation.

September 2011

Research and Development Tax Credits.

Click here

Submission to HM Treasury in response to Further Consultation.

September 2011

Contribution to Debate on UK Pharmaceutical Pricing.

Click here

Defence of PPRS in response to article criticising it.

August 2011

Is it possible for NICE to be objective about pharmaceutical pricing?

Click    here

Guest blog written by Barbara for 2020health think tank.

August 2011

The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines.

Click here

Guest blog written by Barbara for 2020health think tank.

July 2011

NHS Reforms - What the UK Government Policy Changes Really Mean.

Click here

Guest blog written by Barbara for 2020health think tank.

June 2011

The UK Needs More Biotechnology Companies.

Click here

Guest blog written by Barbara for 2020health think tank.

May 2011

The Future of Pharmaceutical R&D.

Click here

Guest blog written by Barbara for 2020health think tank.

April 2011

A new value-based approach to the pricing of branded medicines: a consultation.


Click here

Submission to Department of Health in response to Consultation.

March 2011

Dept. of Health Consultation on Drug Pricing: “A new value-based approach to the pricing of branded medicines”.

Click       here

Guest blog written by Barbara for 2020health think tank.

March 2011

Response to HM Treasury Informal Consultation on R&D Tax Credits.


Click
     here 

Submission to HM Treasury in response to consultation document.

February 2011

Response to HM Treasury Informal Consultation on the Patent Box.

Click       here

Submission to HM Treasury in response to consultation document.

February 2011

How to encourage pharmaceutical R&D.


Click       here

Guest blog written by Barbara for 2020health think tank.

February 2011

NHS Reforms: Health and Social Care Bill 2011.                 


Click       here                                     

Guest blog written by Barbara for 2020health think tank.

January 2011

Which Drugs are the Most Innovative?

Click here

Guest blog written by Barbara for 2020health think tank.

November 2010

Nice Move on Drug Pricing but Where Next?


Click here 

Guest blog written by Barbara for 2020health think tank.

November 2010

Liberating the NHS Revisited

Click here

Blog written by Barbara for 2020health think tank.

October 2010

Liberating the NHS: Transparency in outcomes- a framework for the NHS.


Click here

Submission to Department of Health in response to White Paper.

October 2010

NATIONAL HEALTH SERVICE COMMENTS re. Liberating the NHS: Commissioning for Patients. 

Click here

Submission to Department of Health in response to White Paper.

October 2010

Comments Re. Equity & Excellence: Liberating the NHS.



Click here

Submission to Department of Health in response to White Paper. A short summary can be viewed     here

September 2010

What Women Want: A Manifesto For Health 2010.




Click here

Wide-ranging publication with articles from 17 women with healthcare expertise. Compiled by 2020health think tank.

March 2010.

Barbara’s article pages 9-12.

Barbara Arzymanow. March 2012. She writes on UK healthcare, notably NHS reforms, pharmaceuticals & biotechnology.
Investment Advisory

  • Co-editor of over a hundred issues of Health & Household Investors’ Brief, a publication for professional investors in pharmaceutical and healthcare securities, between 1984 and 1996. The publication was produced by the same team successively at three stockbroking firms: Greenwell, Kleinwort Benson Securities and Robert Fleming Securities.
  • An author of numerous investment reports on pharmaceutical and healthcare companies and on the industry between 1984 and 1996.
  • Her investment advisory work prior to 1996 was widely quoted in the national press in the UK and USA, as was usual at the time for leading investment analysts covering international business sectors.
Barbara Arzymanow
Academic Research Published in Medical Journals

Arzymanow BJ & Kemplay SK (1981) Change with age in the motor endplate in the sternocostalis muscle in the rat. Journal of Anatomy 132: 468

Arzymanow  BJ, Hayes BP & Webster KE (1981) Midbrain neurons outside the isthmo-optic nucleus projecting to the eye in adult birds. Journal of Anatomy 133: 650

Webster KE, Arzymanow BJ, O’Hara PT & Lieberman AR (1981) Transneuronal labelling of the visual portion of the thalamic reticular nucleus in the rat. Journal of Anatomy 133: 652

Arzymanow BJ, Gonzalo A & Lieberman AR (1983) Interneurons in the dorsal lateral geniculate nucleus (LGd) of the rabbit. Journal of Physiology 340: 47P

Jeffery G, Arzymanow BJ & Lieberman AR (1983) Does the early exuberant retinal projections to the superior colliculus in the neonatal rat develop synaptic connections. Developmental Brain Research 14: 135-138

Gonzalo A, Arzymanow BJ & Lieberman AR (1985) Primary optic projections in the rabbit. Study using the horseradish peroxidise anterograde labelling technique. Revista Española de Fisiología 41: 161-170

THIS PAGE WAS LAST UPDATED ON 3RD MAY 2015.

Barbara Arzymanow